FDA warning letter · Drugs

Advanced Cosmetic Research Laboratories Inc.

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).

Passage 2

You failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as **(b)(4)** Antibacterial Acne Soap, and maintain it in a good state of repair.

Passage 3

Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 201.128
  • 21 CFR 210
  • 21 CFR 211.58
  • 21 CFR 211.22(a)
  • 21 CFR 330